Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002622 · ClinicalTrials.gov registry record · Phase 3

Talc in Treating Patients With Malignant Pleural Effusion

A Phase 3 study of Metastatic Cancer, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 3
Development phase
501
Enrollment target
20
Study locations

NCT00002622 is a Phase 3 study of Metastatic Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 501 participants, above the 439-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (14% higher). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002622, a Phase 3 study of Metastatic Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 3
Development phase
501 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Talc may relieve malignant pleural effusion. It is not yet known whether wet talc is more effective than dry talc in treating patients with malignant pleural effusion. PURPOSE: Randomized phase III trial to compare the effectiveness of wet talc with dry talc in treating patients with malignant pleural effusion.

Conditions Studied

Metastatic Cancer

Interventions

  • DRUG talc
  • DRUG Talc

Study Locations (20)

California

  • Providence Saint Joseph Medical Center - Burbank - Burbank
  • Mount Diablo Medical Center - Concord
  • Beckman Research Institute, City of Hope - Duarte
  • California Cancer Center - Fresno
  • Saint Agnes Cancer Center - Fresno
  • Glendale Memorial Hospital and Health Center - Glendale
  • Sutter Health Western Division Cancer Research Group - Greenbrae
  • Loma Linda University Medical Center - Loma Linda
  • Veterans Affairs Medical Center - Long Beach - Long Beach
  • Kaiser Permanente Medical Center - Los Angeles - Los Angeles

Alabama

  • Veterans Affairs Medical Center - Birmingham - Birmingham
  • University of Alabama Comprehensive Cancer Center - Birmingham
  • Huntsville Hospital System - Huntsville
  • Urology Associates - Mobile AL - Mobile
  • MBCCOP - University of South Alabama - Mobile
  • Alabama Oncology, LLC - Montgomery
  • Radiation Oncology Associates of West Alabama - Tuscallosa

Arizona

  • CCOP - Scottsdale Oncology Program - Scottsdale
  • Arizona Cancer Center - Tucson

Alaska

  • Providence Cancer Therapy Center - Anchorage

Trial Details

FieldValue
Enrollment Target 501 participants
Start Date 1994-12
Est. Completion 2006-01
Phase Phase 3

Sponsor

Alliance for Clinical Trials in Oncology

446 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00002622

The ClinicalTrials.gov registry entry for NCT00002622 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 501 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 439-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (14% higher). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which talc is the first listed.

NCT00002622 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT00002622 about?

NCT00002622 is a clinical study titled "Talc in Treating Patients With Malignant Pleural Effusion". RATIONALE: Talc may relieve malignant pleural effusion. It is not yet known whether wet talc is more effective than dry talc in treating patients with malignant pleural effusion. PURPOSE: Randomized phase III trial to compare the effectiveness of wet talc with dry talc in treating patients with mal...

What is the current status of trial NCT00002622?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 501 participants. The study started on 1994-12. Estimated completion is 2006-01.

What conditions does trial NCT00002622 study?

This clinical trial studies the following conditions: Metastatic Cancer.

What interventions are being tested in trial NCT00002622?

The interventions under investigation include: talc (DRUG), Talc (DRUG).

Who is sponsoring clinical trial NCT00002622?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002622 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.